Literature DB >> 21733073

Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease.

Daniel J Moskovic1, Byron Alex, Judy M Choi, Christian J Nelson, John P Mulhall.   

Abstract

OBJECTIVE: • To assess factors that predict penile curvature responses to intralesional verapamil (ILV) injection therapy for men with Peyronie's disease (PD). PATIENTS AND METHODS: • Men with PD for <1 year were assessed at baseline and after 3 months of bi-monthly ILV-injection therapy. Curvature was assessed at the time of maximum penile rigidity. • Univariate relationships were tested with correlation or chi-square analyses. • Multivariate analyses included logistic and linear regression. • We analysed curvature improvement, defined as a decrease of ≥10 ° from baseline. Additionally, the relationship between curvature outcomes and patient age and degree of baseline penile curvature were assessed.
RESULTS: • Data from 131 men were included and the rates of penile curvature change were:26% improved, 12% worsened, and 62% stable. • Age (r=-0.24, P < 0.01) and larger baseline penile curvature (r= 0.33, P < 0.01) were associated with improved curvature on univariate analysis. • On multivariate analysis (logistic regression), both age [odds ratio (OR) 0.93, P < 0.01, 95%CI 0.89-0.97] and larger baseline penile curvature (OR 1.07, P < 0.01, 95%CI 1.04-1.11) were associated with improvements in curvature after ILV-injection therapy. • Improvements in curvature were associated with age (≤40 years vs >40 years; OR 0.27, P < 0.05, 95%CI 0.10-0.75) and degree of penile curvature at baseline (≤30 ° vs >30 °; OR 9.12, P < 0.01, 95%CI 1.94-42.84) when dichotomized as indicated.
CONCLUSION: • Younger age and larger baseline penile curvature were predictive of favourable curvature outcomes. • Analysis of dichotomized variables suggests that age and baseline curvature thresholds may be important to consider when deciding on ILV as a therapeutic strategy for PD.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733073     DOI: 10.1111/j.1464-410X.2010.10029.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

2.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

Review 3.  The non-surgical treatment of peyronie disease: 2013 update.

Authors:  Eric James Shaw; Gregory Clyde Mitchell; Ronny B Tan; Premsant Sangkum; Wayne John G Hellstrom
Journal:  World J Mens Health       Date:  2013-12-24       Impact factor: 5.400

4.  Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease.

Authors:  Lucio Dell'Atti
Journal:  Urol Ann       Date:  2015 Jul-Sep

Review 5.  Lengthening strategies for Peyronie's disease.

Authors:  Christopher D Gaffney; Matthew J Pagano; Aaron C Weinberg; Alex C Small; Franklin E Kuehas; Paulo H Egydio; Robert J Valenzuela
Journal:  Transl Androl Urol       Date:  2016-06

Review 6.  Peyronie's disease: What's around the bend?

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Indian J Urol       Date:  2016 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.